What SEC filings does Karyopharm Therapeutics Inc. submit to the SEC?

Karyopharm Therapeutics Inc. (KPTI) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about KPTI?

A Form 4 for KPTI discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Karyopharm Therapeutics Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for KPTI?

The 10-K is Karyopharm Therapeutics Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all KPTI SEC filings directly on EDGAR?

You can view all historical Karyopharm Therapeutics Inc. filings on the SEC EDGAR company page for KPTI. Each filing card on this page links directly to the original SEC document.

How often does Karyopharm Therapeutics Inc. file with the SEC?

Karyopharm Therapeutics Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling KPTI shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

KPTI SEC Filing News — Karyopharm Therapeutics Inc.

Latest SEC filings for Karyopharm Therapeutics Inc. (KPTI) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-14.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for th…

Sector: Healthcare Industry: Biotechnology Market Cap: $7.8M CIK: 1503802

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for KPTI currently lean bearish. Of the 20 filing records displayed, 5 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

KPTI Filing Activity Snapshot 2026-05-15 — 2026-10-14

Insider Transactions (Form 4)

0 buys vs 5 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$3.9K

Rangwala Reshma (EVP & Chief Medical Officer) · 2026-05-15

408 shares · Form 4

Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Karyopharm Therapeutics Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 6 compensation award and 5 open-market sale. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×6: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×5: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market sale Insider Selling 2026-10-02

KPTI insider Abate Kristin (Chief Accounting Officer) sold 378 shares (~$449.82)

Abate Kristin, listed as Chief Accounting Officer at Karyopharm Therapeutics Inc., reported an open-market sale of 378 KPTI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	378	$1.19	$449.82

Filing: Form 4 (Insider Transaction) Insider: Abate Kristin (Chief Accounting Officer) Shares: 378 Est. Value: $449.82

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-02

KPTI insider Abate Kristin (Chief Accounting Officer) sold 19 shares (~$38.38)

Abate Kristin, listed as Chief Accounting Officer at Karyopharm Therapeutics Inc., reported an open-market sale of 19 KPTI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	19	$2.02	$38.38

Filing: Form 4 (Insider Transaction) Insider: Abate Kristin (Chief Accounting Officer) Shares: 19 Est. Value: $38.38

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-30

KPTI insider Poulton Stuart (EVP, Chief Development Officer) sold 189 shares (~$1.3K)

Poulton Stuart, listed as EVP, Chief Development Officer at Karyopharm Therapeutics Inc., reported an open-market sale of 189 KPTI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	189	$7.10	$1.3K

Filing: Form 4 (Insider Transaction) Insider: Poulton Stuart (EVP, Chief Development Officer) Shares: 189 Est. Value: $1.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-26

KPTI insider Form 4 filed for equity award, exercise, or tax withholding

Greene Barry E (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,508	—	—

Filing: Form 4 (Insider Transaction) Insider: Greene Barry E (Director) Shares: 15,508

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-26

KPTI insider Form 4 filed for equity award, exercise, or tax withholding

Oliger Christy J. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,508	—	—

Filing: Form 4 (Insider Transaction) Insider: Oliger Christy J. (Director) Shares: 15,508

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-26

KPTI insider Form 4 filed for equity award, exercise, or tax withholding

PAKIANATHAN DEEPIKA (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,508	—	—

Filing: Form 4 (Insider Transaction) Insider: PAKIANATHAN DEEPIKA (Director) Shares: 15,508

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-26

KPTI insider Form 4 filed for equity award, exercise, or tax withholding

Schor Chen (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,508	—	—

Filing: Form 4 (Insider Transaction) Insider: Schor Chen (Director) Shares: 15,508

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-26

KPTI insider Form 4 filed for equity award, exercise, or tax withholding

Su Zhen (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,508	—	—

Filing: Form 4 (Insider Transaction) Insider: Su Zhen (Director) Shares: 15,508

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-26

KPTI insider Form 4 filed for equity award, exercise, or tax withholding

BOHLIN GAREN G (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,508	—	—

Filing: Form 4 (Insider Transaction) Insider: BOHLIN GAREN G (Director) Shares: 15,508

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-05-15

KPTI insider Poulton Stuart (EVP, Chief Development Officer) sold 403 shares (~$3.8K)

Poulton Stuart, listed as EVP, Chief Development Officer at Karyopharm Therapeutics Inc., reported an open-market sale of 403 KPTI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	896	—	—
`S`	Open-market sale	403	$9.50	$3.8K

Filing: Form 4 (Insider Transaction) Insider: Poulton Stuart (EVP, Chief Development Officer) Shares: 403 Est. Value: $3.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-05-15

KPTI insider Rangwala Reshma (EVP & Chief Medical Officer) sold 408 shares (~$3.9K)

Rangwala Reshma, listed as EVP & Chief Medical Officer at Karyopharm Therapeutics Inc., reported an open-market sale of 408 KPTI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	947	—	—
`S`	Open-market sale	408	$9.50	$3.9K

Filing: Form 4 (Insider Transaction) Insider: Rangwala Reshma (EVP & Chief Medical Officer) Shares: 408 Est. Value: $3.9K

View on SEC EDGAR → Open Filing Document →

Material Events 8 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 8 in this period for Karyopharm Therapeutics Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-14

KPTI filed 8-K — material company event

Karyopharm Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.